Anti-Diabetic Activity of Polypeptide-K Isolated from Momordica Charantia: A Retrospective Study of 142 Cases

Yong Yean Sirn1, Lee Cheng Lok1, Pak Hoe Weng2, Zuraini Ahmad2 and Muhammad Nazrul Hakim2,3*

1Well Again Clinic Holistic Healthcare, 46150, Petaling Jaya, Malaysia.
2Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Malaysia.
3Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Malaysia
*Corresponding Author E-mail: nazrulh@upm.edu.my

https://dx.doi.org/10.13005/bpj/2298

(Received: 22 June 2021; accepted: 08 September 2021)

Diabetes Mellitus occurs when the pancreas fails to produce sufficient insulin, or the body is unable to use the insulin produced effectively. In order to regulate the blood glucose of diabetic patients, Diabegard®, a herbal antidiabetic medicine and daily supplement, contains polypeptide-k which exists in the seed of Momordica Charantia (bitter gourd) was prescribed. Purpose: A retrospective study is therefore done with the aim to examine the effectiveness of Diabegard®, polypeptide-k in regulating the blood glucose and cholesterol level of diabetic patients who took Diabegard® for four weeks with a dose of 60 mg per day. Methods: A database record of 105 male and 37 female (ages 25-81) treated with Diabegard®, polypeptide-k was assessed. The effectiveness of Diabegard®, polypeptide-k in blood glucose regulation was determined based on four aspects: gender, three different age categories, four different categories of duration of the disease and five different categories of severity of the disease. The Pearson’s correlation was used to find the correlation among variables. Paired sample t-test was used to compare the means of pre- and post-treatment of blood glucose level. One-way ANOVA was used to compare the means of different groups for each aspect. Results: Result showed that age and duration of disease (r²=0.469), pre-treatment of blood glucose and post-treatment of blood glucose (r²=0.606) showed positive relationship. Both paired sample T-test of pre-and post-treatment of blood glucose showed significant difference (p<0.05). Categories with very mild (7 mmol/L), severe (13.9-19.4mmol/L) and very severe (>19.4mmol/L) diabetes showed significant difference (p<0.05). Other tests showed no significant difference. Conclusion: In conclusion, this present retrospective study showed that Diabegard®, polypeptide-k was effective in controlling blood glucose level of all diabetic patients especially in patients with mild (26.87% reduction), severe (40.43% reduction) and very severe diabetes (49.27% reduction).

Keywords: Clinical cases; Diabetes; Momordica charantia; Polypeptide k; Retrospective study.
DM is a metabolic disorder of carbohydrate, protein and fat metabolism characterized by increased fasting and postprandial blood glucose levels (Yuan et al., 2008). DM is a major contributor to morbidity and mortality and generates large direct and indirect costs (American Diabetes Association, 2008). Besides causing long-term complications, it is an important risk factor for cardiovascular diseases (Yeh et al., 2003). The potential complications may be delayed, lessened or prevented by maintaining blood glucose values close to normal.

Besides the use of insulin for treatment of insulin dependent DM, other approaches to prevent hyperglycemia include the use of amylase analogues which regulate gastric emptying and inhibitors of intestinal alpha glucosidases such as acarbose, miglitol and voglibose which delay postprandial hyperglycemia. Sulphonylureas act by closure of ATP dependent channel. Metformin, a biguanide oral antibiotic, limits glucose absorption in intestine (Jaspreet Virdi et al., 2003).

Although different types of synthetic oral hypoglycemic agents and insulin are available for the treatment of DM, insulin cannot be taken orally and the synthetic agents in use can produce serious side effects and toxicity (Yuan et al., 2008). Examples of possible side effects are causing hypoglycemia at higher doses, lactic acidosis, liver problems and diarrhea. Due to the side effects of the currently used drugs, there is an urgent need for a safe agent with minimal adverse effects, which can be taken for a longer duration (Jaspreet Virdi et al., 2003). Therefore, in the past decade, research has been focused on scientific evaluation of traditional drugs of plant origin (Grover and Yadav, 2004) to treat non-insulin dependent DM (Jaspreet Virdi et al., 2003).

World plant biodiversity is the largest source of herbal medicine. There is still about 60-80% world population relying on plant-based medicines which are being used since the ages as traditional health care systems. Although the traditional Indian system of medicine has a long history of use, they lack adequate scientific documentation, especially in light modern scientific knowledge. However, it is now clear that the medicinal value of these plants lies in the bioactive phytochemical constituents that produce definite physiological effects on human body.

Traditional medicines all over the world have advocated the use of herbs to treat diabetes since time unmemorabel. *Momordica charantia* Linn (bitter gourd) is one such plant that has been frequently and extensively used and reported for its hypoglycemic effect (Grover and Yadav, 2004; Day et al., 1990). It has been commonly used as a traditional remedy in Asia, Africa, England, India, Sri Lanka and etc (Ali et al., 1993).

Fruit and seeds of bitter gourd are traditionally used as a medicinal herb and/or vegetable for treatment of diabetes in Southeast Asian countries (Senanayake et al., 2004). Its hypoglycemic activity has been reported in pulps, seeds and leaves in vivo (Xiang et al., 2007). Khanna et al. (1981) isolated an active protein (polypeptide-p) from seeds by acid ethanol extraction, which decreased blood glucose in Streptozotocin-induced diabetic rats and increased the glycolytic enzymes activity. Polypeptide-p has also shown to have hypoglycemic effect in juvenile and maturity-onset diabetic patients (Khanna et al., 1981; Jaspreet Virdia et al., 2003).

There is increased interest in finding a naturally occurring plant-based compound – a functional food ingredient, which could prevent and/or ameliorate DM (Schakel et al., 2008). One such food ingredient is said to have this potential is polypeptide-k. Polypeptide-k is a functional food ingredient that is extracted from seeds of bitter gourd. It has high homology with human insulin and helps in rejuvenating pancreas and activates inactive insulin. It contains 18 standard amino acids in a single molecule and its application as a food ingredient may help in reducing increased blood glucose level and prevention of diabetes (Khanna, 2004). Research and clinical trials have proven that this product is successful in blood glucose regulation, rejuvenation of beta-cells in the pancreas and inhibiting the process of glycation (which is responsible for the side-effects of diabetes) (Cancer Journal, 2008).

The extraction of polypeptide-k from the seeds of bitter gourd (Nazrul Hakim, 2011) is a batch process in the sequence of different unit operations such as extraction, purification, precipitation and crystallization, filtration, size reduction, washing, drying, sterilization and packing (Ahmad et al, 2012). Diabegard®, an herbal medicine and daily supplement, which is safe and
well-tolerated (Lee et al. 2011). Therefore, the objective of this retrospective study was to examine the effectiveness of Diabegard® polypeptide-k in regulating the blood glucose level of diabetic patients who took Diabegard® for four weeks with a dose of 60 mg per day (Sirn et al. 2014).

**MATERIALS AND METHODS**

Patients’ medical records were accessed to collect all relevant demographic and medical data such as age, gender, duration of disease, pre- and post-treatment of blood glucose level, and pre- and post-treatment of cholesterol level. However, over 300 patients’ medical records, only 142 patients’ data were complete with the information that is necessary and essential for the study. Patients studied were all from private hospital in Kuala Lumpur, Malaysia.

**Data grouping**

In order to compare the effectiveness of Diabegard® into more detailed, age, gender, duration of disease and severity of disease were divided into several categories as follows:

**Statistical analysis**

**Comparison between pre- and post-treatment of blood glucose level**

Paired sample t-test is performed to test significant difference between pre-treatment and post-treatment of blood glucose. Results are expressed as standard error means (S.E.M). Standard error mean is used to depict the deviation in the estimate of the means. Significance of the differences between the pre-treatment and post-treatment of blood glucose level at p<0.05.

**Comparison mean between age group and blood glucose level**

One-way ANOVA and Turkey’s post hoc test was performed to test the significant difference between these two means. Results are expressed as standard error means (S.E.M). Standard error mean is used to depict the deviation in the estimate of the means. Variations are considered existent if the difference was significant at the 5% level.

**Compare relationships among factors**

Pearson correlation was performed to test the relationships among all factors. Positive value has positive relationship and vice versa. Magnitudes of value show how strong the relationships are. Correlation is significant at p<0.05.

**RESULT AND DISCUSSION**

Table 2 illustrated the mean ± SEM of both pre- and post-treatment of blood glucose level. The mean of pre-treatment of blood glucose

| Category | Age Group | No. of cases |
|----------|-----------|--------------|
| 1        | 21-40     | 14           |
| 2        | 41-60     | 98           |
| 3        | 61-80     | 30           |

| Category | Duration of Disease Group | No. of cases |
|----------|---------------------------|--------------|
| 1        | 0-10                      | 106          |
| 2        | 11-20                     | 25           |
| 3        | 21-30                     | 8            |
| 4        | 31-40                     | 2            |

| Category | Severity of Disease Group | Range | No. of cases |
|----------|---------------------------|-------|--------------|
| 1        | very mild                 | <7    | 3            |
| 2        | mild                      | 7-8.2 | 6            |
| 3        | moderate                  | 8.3-13.8 | 66         |
| 4        | severe                    | 13.9-19.4 | 52         |
| 5        | very severe               | >19.4 | 15           |
level was 14.23 mmol/L. After taken Diabegard® polypeptide-K for almost one month, the mean of blood glucose level dropped prominently to 9.01 mmol/L. By using SPSS, both means of pre- and post-treatment of blood glucose level were compared using paired-sample T-test. It showed significant difference between the two means. In other words, it suggested that after taken Diabegard® polypeptide-K, patients were able to control their blood sugar level close to normal level and prevent any complications due to diabetes mellitus. Khanna (2004) reported that polypeptide-K is able to reduce blood glucose level in diabetic patients. Polypeptide-K contains 18 standard amino acids in a single molecule and its application as a food ingredient may help in reducing blood glucose level and prevention of diabetes which was proposed previously.

In this present study, among the 142 patients, we categorized them into 3 categories: young adult (21-40), adult (41-60) and elderly (61-80). The number of adult diabetic patient ranked the first (98 people), followed by elderly (30 people) and young adult (14 people). This was similar to the finding reported previously by King et al. (1998) that in developing countries (eg. Malaysia), the majority of people with diabetes are in 45-64 year age range. All three different categories in table 4.3.1 showed prominent decrease in mean of pre- and post-treatment of blood glucose level with the adult category showed the highest decrease about 35.11%. Turkey’s post hoc test was performed, and we found that no significant difference among the

### Table 2. Comparison between pre- and post-treatment of blood glucose level

| Group       | Blood glucose level (mmol/L) |
|-------------|------------------------------|
| Pre-treatment | 14.23± 0.34                  |
| Post- treatment | 9.01± 0.19*                 |

n= 142, Values are mean± SEM  
* mean shows statistically significant (p<0.05) from pre-treatment of blood glucose level

### Table 3. Compare mean between age group and blood glucose level (mmol/L)

| Category | Age Range (years) | n(%) | pre-treatment | post-treatment | glucose reduction (pre-post-treatment) | % blood glucose reduction |
|----------|-------------------|------|---------------|----------------|----------------------------------------|--------------------------|
| 1        | 21-40             | 14(9.86) | 13.31± 1.07*  | 8.75± 0.77*    | 4.56± 0.59                            | 33.94± 2.70              |
| 2        | 41-60             | 98(69.01) | 14.53± 0.41*  | 9.05± 0.22*    | 5.48± 0.35                            | 35.11± 1.50              |
| 3        | 61-80             | 30(21.13) | 13.67± 0.71*  | 9.01± 0.46*    | 4.66± 0.51                            | 31.70± 2.75              |

Values are mean± SEM  
*a* mean significant at p<0.05

### Table 4. Compare mean between severity of disease group and blood glucose level (mmol/L)

| Severity of disease Category | Type | Range (mmol/L) | n(%) | pre-treatment | post-treatment | glucose reduction (pre minus post-treatment) | % blood glucose reduction |
|-----------------------------|------|----------------|------|---------------|----------------|----------------------------------------------|--------------------------|
| 1                           | very mild | <7         | 3(2.11) | 6.75± 0.77*  | 4.92± 0.61*    | 1.82± 0.66                                  | 26.87± 9.59              |
| 2                           | mild | 7.8-13.8 | 6(4.23) | 7.78± 0.15*  | 6.24± 0.50*    | 1.54± 0.56                                  | 19.44± 6.82              |
| 3                           | moderate | 8.3-13.8 | 65(45.78) | 11.53± 0.17* | 8.30± 0.15*    | 3.23± 0.17                                  | 27.50± 1.31              |
| 4                           | severe | 13.9-19.4 | 53(37.32) | 16.55± 0.20* | 9.84± 0.32d | 6.70± 0.32                                  | 40.43± 1.75              |
| 5                           | very severe | >19.4 | 15(10.56) | 21.79± 0.42d | 11.10± 0.78d | 10.69± 0.68                                  | 49.27± 3.22              |

Values are mean± SEM  
*a,b,c,d* mean with different superscript are significant at p<0.05
Table 5. Compare mean between duration of disease group and blood glucose level (mmol/L)

| Duration of disease Category | Range (years) | n(%) | pre-treatment | post-treatment | glucose reduction (pre-post-treatment) | % blood glucose reduction |
|------------------------------|---------------|------|---------------|---------------|----------------------------------------|--------------------------|
| 1                            | 0-10          | 106(75.18) | 14.16±0.39a | 8.90± 0.22b | 5.25± 0.31 | 34.84± 1.39 |
| 2                            | 11-20         | 25(17.73)  | 14.13±0.87a | 9.34± 0.51b | 4.80± 0.60 | 31.53± 2.78 |
| 3                            | 21-30         | 8(5.67)    | 15.06±1.47a | 9.86± 0.79b | 5.20± 1.22 | 31.92±5.74  |
| 4                            | 31-40         | 2(1.42)    | 13.36±4.47a | 8.89±2.22b | 4.47±2.25 | 31.33±6.36  |

Values are mean± SEM

* means with different superscript differ significant at p<0.05

Table 6. Compare mean between gender group and blood glucose level (mmol/L)

| Gender Category | Type | N (%) | pre-treatment | post-treatment | glucose reduction (pre-post-treatment) | % blood glucose reduction |
|-----------------|------|-------|---------------|---------------|----------------------------------------|--------------------------|
| 1               | Male | 105(73.94) | 14.25±0.37a | 9.04±0.20a | 5.21±0.30 | 34.41±1.37 |
| 2               | Female | 37(26.06)  | 14.15±0.80a | 8.93±0.47a | 5.22±0.60 | 33.87±2.62 |

Values are mean± SEM

* means with different superscript are significant at p<0.05

three age categories. In other words, Diabegard® polypeptide-K was effectively reducing all elevated blood glucose level in all categories. Jaspreet Virdia et al. (2003) reported that in 2007 the Philippine Department of Health issued a circular stating that Momordica charantia as a scientifically validated herbal medicinal plant can lower elevated blood glucose levels in all individual.

In table 4, we categorized all 142 diabetic patients into 5 categories according to their level of severity of diabetes mellitus. Patients with blood glucose level of <7mmol/L is considered very mild diabetes (category 1), 7-8.2mmol/L is mild diabetes (category 2), 8.3-13.8mmol/L is moderate diabetes (category 3), 13.9-19.4mmol/L is severe diabetes (category 4) and >19.4mmol/L is very severe diabetes. From the table, we noticed that category 5 diabetic patients showed the highest percentage of blood glucose reduction around 49%. For percentage of blood glucose reduction, Turkey’s post-hoc test showed significant difference between category 1 and 4 and between category 1 and 5. Both category 4 and 5 showed almost double the reduction value shown by category 1. This suggested that Diabegard® polypeptide-K worked effectively in very severe diabetic and followed by severe diabetic patients. Patients in these two categories were normally having non-functioning insulin. Polypeptide-K has high homology with human insulin and helps in rejuvenating pancreas and activates inactive insulin (Khanna, 2004).

All the 142 patients were categorized into 4 categories based on their duration of years having diabetes mellitus as shown in table 4.3.5. The majority are in the first category. Although category 1 had the greatest percentage of blood glucose level reduction (35%), the other three groups showed no big differences (category 2 (31.53%), category 3 (31.92%) and category 4 (31.33%)). Turkey’s test also showed no significant differences among the four categories. Hence, Diabegard® polypeptide-K had the same effect on all diabetic patients. Research and clinical trials had proven that this product was successful in blood glucose regulation, rejuvenation of beta-cells in the pancreas and inhibiting the process of glycation.
(which is responsible for the side-effects of diabetes) in all Diabegard® users (Cancer Journal, 2008).

We compared the means between gender groups with blood glucose level. There were two categories: male and female. Male has greater number (105) than female (37). However, the percentage of blood glucose reduction in both gender showed no big difference: male (34.41%) and female (33.87%). From the Turkey’s post-hoc test, no significant different was found between groups. It suggested that both male and female who took Diabegard® polypeptide-K had decreased their elevated blood glucose level. In the study done by Naik et al. (2009), standardized preparation of ethyl acetate fraction of Momordica charantia extract elicited promising hypoglycemic activity in both gender of animal experiments and seem to be a potential candidate to be investigated in the management of diabetes or other hypoglycemic associated disorders in clinical medicine.

On the other hand, after examining the relationship among all variables using Pearson correlation, result showed that age and duration of disease ($r^2=0.469$), pre-treatment of blood glucose and post-treatment of blood glucose ($r^2=0.606$), pre-treatment of cholesterol and post-treatment of cholesterol ($r^2=0.558$) showed positive relationship.

From the result in this present study, Diabegard® Polypeptide-K has reduced blood glucose level about 36%. It is better than prescription drug (Metformin) which is just having efficacy around 20% (Silvio et al., 1998). Metformin is usually prescribed by physician to treat diabetic patients. It acts primarily by decreasing endogenous glucose production. It does not stimulate insulin secretion in the body but acts to increase sensitivity of peripheral tissue to insulin. Diabegard® Polypeptide-K is believed to act through the same mechanism by activating enzyme AMPK which is responsible for glucose uptake. However, more studies have to been done to investigate its mechanism. In comparison, Diabegard® Polypeptide-K is safer than Metformin in regulating blood glucose level of diabetic patients because Metformin causes adverse effects such as diarrhea, nausea etc. However, Diabegard® Polypeptide-K does not have any known side effect.

DM is a metabolic disorder of carbohydrate, protein and fat metabolism characterized by increased fasting and postprandial blood glucose levels. The prevalence of diabetes in the world is 171 million while in 2030 it is predicted to exceed 366 million. On the other hand, the prevalence of diabetes in Malaysia is 0.9 million in 2000 and it is estimated to reach 2.4 million in 2030. Conventional treatments of diabetes mellitus include injection of insulin, the use of amylin analogues acarbose, miglitol and voglibiose, sulphonylureas, metformin. Some are in great concern about the potential side-effects such as causing hypoglycemia at higher doses, lactic acidosis, liver problems and diarrhea.

Traditional medicines all over the world have advocated the use of herbs to treat diabetes since time unmemorable. Momordica charantia Linn (bitter gourd) is one such plant that has been frequently and extensively used and reported for its hypoglycemic effect. Polypeptide-k is a functional food ingredient that is extracted from seeds of bitter gourd. It has high homology with human insulin. It contains 18 standard amino acids in a single molecule and its application as a food ingredient may help in reducing increased blood glucose level and prevention of diabetes.

From the present study, Diabegard® polypeptide-K had reduced the blood-glucose level close to normal level among diabetic users who took Diabegard® for one month. Pre-treatment of blood glucose level was reduced from 14.23mmol/L (mean) to 9.01mmol/L (mean). All three categories of age range: young adult (21-40), adult (41-60) and elderly (61-80) were also demonstrated satisfactory blood glucose reduction after taking Diabegard®. Among these three groups, adult gategort showed the highest decrease about 35.11 %. Next, all 142 diabetic patients were categorized into 5 categories according to their level of severity of diabetes mellitus: $\leq$7mmol/L is very mild diabetes (category 1), 7-8.2mmol/L is mild diabetes (category 2), 8.3-13.8mmol/L is moderate diabetes (category 3), 13.9-19.4mmol/L is severe diabetes (category 4) and $> 19.4$mmol/L is very severe diabetes. Category 5 diabetic patients showed the highest percentage of blood glucose reduction around 49%. Both category 4 and 5 showed almost double the reduction value
showed by category 1. Patients were divided into 4 categories based on their duration of years having diabetes mellitus. Category 1 had the greatest percentage of blood glucose level reduction (35%), the other three groups showed no big differences (category 2 (31.53%), category 3 (31.92%) and category 4 (31.33%)). Lastly, patients were again divided in to two gender group: male and female. The percentage of blood glucose reduction in both genders showed no big difference: male (34.41%) and female (33.87%). In conclusion, Diabegard® polypeptide can decrease and control the elevated blood sugar level close to normal level in order to prevent complication.

REFERENCES

1. A.K. Shetty, G. Suresh Kumar, K. Sambaiah and P.V. Salimah. Effect of Bitter Gourd (Momordica charantia) on Glycaemic Status in Streptozotocin Induced Diabetic Rats. Plant Foods Hum Nutr. 60(3):109-112 (2005).

2. Ahmad Z, Zanhuri KF, Yaacob A, Chiong HS, Selvarajah M, Ismail A, Hakim MN. In Vitro Anti-diabetic Activities and Chemical Analysis of Polypeptide-k and Oil Isolated from Seeds of Momordica charantia (Bitter Gourd). Molecules. 10(17)(8):9631-40 (2012).

3. Ahmed, I., Adeghate, E., Sharma, A.K., Pallot, D.J. and Singh, J. Effect of Momordica charantia Fruit Juice on Islet Morphology in the Pancreas of Streptozotocin Diabetic Rat. Diabet Res Clin Pract. 40:145-151 (1998).

4. Alessandra Braca, Tiziana Siciliano, Manuela D’Arrigo, Maria Paola Germano. Chemical Composition and Antimicrobial Activity of Momordica charantia Seed Essential Oil. Fitoterapia. 79(2): 123-125 (2008).

5. Ali L., Khan A. K. and Mamun M. L. Studies on Hypoglycemic Effect of Fruit Pulp, Seed and Whole Plant of Momordica charantia on Normal and Diabetic Model Rats. Planta Med. 59:408-412 (1993).

6. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2007. Diabetes Care. 31: 596-615 (2008).

7. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 138:271-281 (2018).

8. Day C., Cartwright T., Provost J. and Bailey C. J. Hypoglycemic Effect of Momordica charantia Extracts. Plant Med. 56:426-429 (1990).

9. Ditta, P.K., Chakravarty, A.K., Chowdhury, U.S. and Paksrashi, S.C. Vicine, A Slavism-inducing Toxin from Momordica charantia Linn, Seeds. Ind Jour Chem. 20B:669-671 (1981).

10. Fuller JH, Elford J, Goldblatt P, Adelstein AM. Diabetes Mortality: New Light on an Undersized Public Health Problem. Diabetologia. 24:336-341 (1981).

11. Giron LM, Freire V, Alonzo A, Caceres A. J Ethnopharmacol; 34:173 (1991).

12. Grover JK, Yadav SP. Pharmacological Actions and Potential Uses of Momordica charantia: A Review. Journal of Ethnopharmacology. 93:123-124 (2004).

13. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and Tolerability of Simvastatin Plus Fenofibrate for Combined Hyperlipidemia. Am J Cardiol. 95(4):462-8 (2006).

14. International Journal of Diabetes Mellitus 2. Raising the Priority Accorded to Diabetes in Global Health and Development: A promising response. 139-140 (2010).

15. Jaspreet Virdi, S. Sivakami, S. Shahani, A.C. Suthar, M.M. Banavalikar, M.K. Biyani. Anti-hyperglycemic Effect of Three Extracts From Momordica charantia. Journal of Ethnopharmacology. 88:107-111 (2003).

16. Kar A., Choudhary B.K. and Bandyopadhyay N.G. Comparative Evaluation of Hypoglycaemic Activity of Some Indian Medicinal Plants in Alloxan Diabetic Rats. Journal of Ethnopharmacology, 1: 105-8 (2003).

17. Khan BB & Flier JS. Obesity and Insulin Resistance. Journal of Clinical Investigation. 106:473-481 (2000).

18. Khanna P, Jain SC, Panagariya A. Hypoglycemic Activity of Polypeptide-p from a Plant Source. Journal of Nat. Prod. 44:648-655 (1981).

19. Khanna P. Protein /Polypeptide-k Obtained from Momordica charantia. United State Patent 6831162 (2004).

20. King H, Aubert RE, Herman WH. Global Burden of Diabetes, 1995-2025: Prevalence, Numerical Estimates and Projections. Diabetic Care. 21: 1414-1431 (1998).

21. Lee CL, Yong YS, Ahmad Z, Yaacob A and Hakim MN. Effects of polypeptide-k supplemented soft bun on blood glucose level in healthy adults. International Journal of Nutrition and Metabolism, 3(1): 7-10 (2011).
Shabib, B.A., Khan, L.A. and Rahman, R.

Meir, P. and Yaniv, Z. An In-vitro Study of the Effect of *Momordica charantia* on Glucose uptake and Glucose Metabolism in Rats. *Planta Med.* 32:12-16 (1985).

Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and Causes of Death in the WHO Multinational Study of Vascular Disease in Diabetes. *Diabetologia*. 44(Suppl.2):S14-S21 (2001).

Naik, Suresh R., Bumrela, Shrinivas B., Lagishetty, Chakradhar V. and Mandik, Rahul V. Probable Mechanism of the Antihyperglycemic Effect of Standardized Extract from *Momordica charantia* in Streptozotocin Diabetic Rats. *Journal of Complementary and Integrative Medicine*. 6(1): Article 27 (2009).

Nazrul-Hakim, M. & Yaacob, A. & Ahmad, Y. & Ahmad, Zuraini. Preliminary toxicological evaluations of polypeptide-k isolated from *Momordica charantia* in laboratory rats. *World Academy of Science, Engineering and Technology*. 51: 757-760 (2011).

Noguchi R., Yasui Y., Suzuki R., Hosokawa M., Noguchi R., Yasui Y., Suzuki R., Hosokawa M., Nakamura R., Sasaki M., Sei Y., Ando T., Ikeda Y. Dietary Effect of Bitter Gourd Oil on Blood and Liver Lipids of Rats. *Archives of Biochemistry & Biophysics*. 396: 373-5 (2001).

Platel K., Shurpalekar K.S., Srinivasan K. Effect of Bitter Gourd (*Momordica charantia*) on Growth and Blood Constituents in Albino Rats. *Nahrung*. 37: 156–160 (1993).

Sathish Kumar D, Vamshi Prakasha K., Yogeshwaran P, Harani A, Sudhakar K, Sudha P, David Banji. A Medicinal Potency of *Momordica charantia* for the Treatment of Diabetic Rats. *International Journal of Pharmaceutical Sciences and Research*. 1(2): 95-100 (2010).

Senanayake GV, Maruyama M, Shibuya K, Sakono M, Fukuda N, Morishita T, Yukizaki C, Kawano M, Ohta H. The Effect of Bitter Melon (*Momordica charantia*) on Serum and Liver Triglyceride Levels in Rats. *Journal of Ethnopharmacology*. 91:257-262 (2004).

Shahib, B.A., Khan, L.A. and Rahman, R. Hypoglycemic Activity of Coccinia indic and *Momordica charantia* in Diabetic Rats: Depression of Hepatic Gluconeogenic Enzymes Glucose-6-phosphatase and Fructose-1,6-bisphosphatase and Elevation of Both Low and Red-cell Shunt Enzyme Glucose-6-phosphate dehydrogenase. *Biochem Jour*. 292:267-270 (1993).

Shrivastava Surabhi and Leelavathi S. Preliminary Phytochemical Evaluation of Leaf Extracts of *Catunaregum spinosum* Thunb. *International Journal of Pharmaceutical Sciences Review and Research*. 3(2):114-118 (2010).

Silvio E. Inzucchi, David G. Maggs, Geralyn R. Spollet, Stephanie L. Page, Frances S. Rife, Veronika Walton and Gerald I. Shulman. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus. *The New England Journal of Medicine*. 338(13):867-872 (1998).

Sriram Y., Lok LC., Ahmad Z., Hakim MN. A Report of Six Clinical Cases of Lowered Blood Cholesterol Profile Associated with Supplementation with Polypeptide K (Diabeegadr®, a Polypeptide Isolated from the Seeds of *Momordica charantia* Linn. *Tropical Journal of Pharmaceutical Research*. 13(9): 1555-1560 (2014).

Soo Kyoung Lee, Seok Hyun Eom, Yong Kyoung Kim, Nam II Park, Sangum Park. Cucurbitane-type triterpenoids in *Momordica charantia* Linn. *Journal of Medicinal Plants Research*. 3(13):1264–1269 (2009).

Spreafico, F., Malifoire, C., Moras, M.L., Marmonti, L., Filippeschi, S., Barbieri, L., Perocco, P., Stirpe, F. The Immunomodulatory Activity of the Plant Proteins *Momordica charantia* Inhibitor and Pokeweed Antiviral Protein. *International Journal of Immunopharmacology*. 5: 335–343 (1983).

Spreafico, F., Malifoire, C., Moras, M.L., Marmonti, L., Filippeschi, S., Barbieri, L., Perocco, P., Stirpe, F. The Immunomodulatory Activity of the Plant Proteins *Momordica charantia* Inhibitor and Pokeweed Antiviral Protein. *International Journal of Immunopharmacology*. 5: 335–343 (1983).

Takemoto, D.J. Purification and Characterization of A Cytostatic Factor with Antiviral Activity from the Bitter Melon. *Preparative Biochemistry*. 13: 371-93 (1983).

United Nations General Assembly. Prevention and Control of Noncommunicable Diseases. *Resolution*, 64/265 (2010).

Vivian A. Fonseca. Clinical Diabetes: Translating Research into Practice. In *Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome* ed. Guillerme E. Umpierrez and Dawn Smiley, pp 102-118. India: Rajkamal Electric Press (2006).
Global Prevalence of Diabetes: Estimates for The Year 2000 and Projections for 2030. *Diabetes Care.* 27:1047-1053 (2004).

42. Xiang L, Huang X, Chen L, Rao P, Ke L. The Reparative Effects of *Momordica charantia* Linn Extract on HIT-T 15 Pancreatic â-Cells. *Asia Pacific Journal of Clinical Nut.* 16(Suppl 1):249-252 (2007).

43. Yeh, G.Y., Eisenberg, D.M., Kaptchuk, T.J., Phillips, R.S. Systemic Review of Herbs and Dietary Supplements for Glycemic Control in Diabetes. *Diabetes Care.* 26(4): 1277-1294 (2003).

44. Yu W, Naim JO, Lanzafame RJ. Effects of Photostimulation on Wound Healing in Diabetic mice. *Lasers Surgical Medicine.* 20:56–63 (1997).

45. Yuan X, Gu X, Tang J. Purification and Characterization of A Hypoglycemic Peptide from *Momordica charantia* L. Var. abbreviate Ser. *Food Chem.*, 111:415-420 (2008).